CN107345235A - The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark - Google Patents
The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark Download PDFInfo
- Publication number
- CN107345235A CN107345235A CN201710544434.1A CN201710544434A CN107345235A CN 107345235 A CN107345235 A CN 107345235A CN 201710544434 A CN201710544434 A CN 201710544434A CN 107345235 A CN107345235 A CN 107345235A
- Authority
- CN
- China
- Prior art keywords
- cerebral apoplexy
- cerebral
- cells
- cell
- cell factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses the application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark, it is related to biological technical field.Result of study of the present invention shows that Th2 cell percentages and its cell factor IL 4 have obvious correlation with cerebral apoplexy especially cerebral arterial thrombosis, Th2 cells and its cell factor IL 4 can be diagnosed as cerebral apoplexy and the biomarker of prognosis instruction, it is a kind of brand-new cerebral apoplexy mark, this provides a kind of new thinking and means for cerebral apoplexy diagnosis and prognosis, be advantageous to accelerate the study of incident mechanism process of cerebral apoplexy, also provide help quickly to filter out the medicine for the treatment of cerebral apoplexy.
Description
Technical field
The present invention relates to biological technical field, in particular to Th2 cells and cell factor IL-4 as cerebral apoplexy mark
The application of will thing.
Background technology
Cerebral apoplexy (Stroke) is that the world today endangers one of main disease of human life and health, wherein ischemic brain
Palsy (Ischemic Stroke, IS) is most common form.Cerebral arterial thrombosis can be divided into 4 kinds of hypotypes, including transience again
Cerebral arterial thrombosis (Transient Ischaemic Attack, TIA), RIND
(Reversibleischemic Neurological Deficit, RIND), advancing stroke (Stroke In
Progression, SIP), complete stroke (Complete Stroke, CS).
The increasingly rejuvenation of cerebral arterial thrombosis morbidity at present, nearest epidemiological study discovery, cerebral arterial thrombosis
The percentage of aged patients about 43%, but 51% is up in impoverished nation's percentage, developed country 34%, this be probably by
Higher cardiovascular risk factors be present in impoverished nation.The morbidity of cerebral arterial thrombosis young patient goes up year by year, Ke Nengyu
Smoking, drink, be fat, the increase of hypertension it is relevant.Therefore, the pathogenesis of cerebral arterial thrombosis is understood fully, finds and effectively controls
Treatment means are most important.
Biomarker refer to detect blood or urine by chemistry or biological method predict physiology or pathological state with
A kind of indicator of disease risk degree.Biomarker is the effective tool in drug development process, and it provides Drug
The relevant information of energy and disease process, reflects specific medication effect.
It is presently used for diagnosing and predicts the method for patient's cerebral arterial thrombosis prognosis or what means relied primarily on is state of the U.S.
Vertical Institutes of Health Research's Stroke Scale (the National Institutes of Health Stroke Scale, NIHSS),
The detection of Barthel indexes and infarct size is carried out.What shortage can quickly and easily be easy to detect can be used for reacting ischemic
Property the cerebral apoplexy state of an illness biomarker, this be understand fully the pathogenesis of cerebral arterial thrombosis, find effective treatment means with
And medicine band carrys out inconvenience.
The content of the invention
It is an object of the invention to provide application of the Th2 cells as cerebral apoplexy mark.
Another object of the present invention is to provide applications of the cell factor IL-4 as cerebral apoplexy mark.
Another object of the present invention is to provide the application of cell factor IL-4 antibody.
What the present invention was realized in：
Application of the Th2 cells as mark in cerebral apoplexy diagnostic kit is prepared.
Application of the Th2 cells as mark in the kit for preparing prediction patients with cerebral apoplexy prognosis.
Cell factor IL-4 is preparing cerebral apoplexy diagnostic kit or is predicting the examination of patients with cerebral apoplexy prognosis as mark
Application in agent box.
Cell factor IL-4 antibody is in preparing cerebral apoplexy diagnostic kit or predicting the kit of patients with cerebral apoplexy prognosis
Application.
The invention has the advantages that：
The present invention relatively comprehensively independently have studied first clinical patient peripheral blood T h2 cells and its cell because
Son and the relation of cerebral arterial thrombosis, as a result show, peripheral blood Th2 cell percentages and its cell factor IL-4 are and NIHSS
Scoring is in inverse ratio, is proportionate with Barthel indexes, is in inverse ratio with cerebral apoplexy patient infarction of brain area, result above shows
Th2 cell percentages and its cell factor IL-4 and cerebral apoplexy especially cerebral arterial thrombosis have an obvious correlation, and Th2 is thin
Born of the same parents and its cell factor IL-4 can be diagnosed as cerebral apoplexy and the biomarker of prognosis instruction, is a kind of brand-new cerebral apoplexy
Mark；Based on this, can using Th2 cells or cell factor IL-4 as mark be applied to prepare cerebral apoplexy diagnostic kit or
Person prepare prediction patients with cerebral apoplexy prognosis the medium field of kit, this be cerebral apoplexy diagnosis and prognosis provide it is a kind of newly
Thinking and means, be advantageous to accelerate cerebral apoplexy study of incident mechanism process, also for quickly filter out treatment cerebral apoplexy medicine
Help is provided.
Brief description of the drawings
In order to illustrate the technical solution of the embodiments of the present invention more clearly, below by embodiment it is required use it is attached
Figure is briefly described, it will be appreciated that the following drawings illustrate only certain embodiments of the present invention, therefore be not construed as pair
The restriction of scope, for those of ordinary skill in the art, on the premise of not paying creative work, can also be according to this
A little accompanying drawings obtain other related accompanying drawings.
Fig. 1 is that the streaming of the Th2 cell percentages contents in different group patient's peripheral bloods that the embodiment of the present invention 1 provides is thin
Born of the same parents' testing result figure；
Fig. 2 is the Th2 cell percentages and NIHSS scorings, Barthel indexes, infarct size that the embodiment of the present invention 1 provides
Correlation analysis result；
Fig. 3 is the IL-4 levels and NIHSS scorings, the phase of Barthel indexes, infarct size that the embodiment of the present invention 2 provides
Closing property analysis result.
Embodiment
, below will be in the embodiment of the present invention to make the purpose, technical scheme and advantage of the embodiment of the present invention clearer
Technical scheme be clearly and completely described.Unreceipted actual conditions person, builds according to normal condition or manufacturer in embodiment
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, it is the conventional production that can be obtained by commercially available purchase
Product.
Application of the Th2 cells and cell factor IL-4 of offer to the embodiment of the present invention below as cerebral apoplexy mark
It is specifically described.
Xiangyang City of Hubei Province central hospital Neurology April 66 days to 2017 March in 2017 is chosen in the research of the present invention
53 Ischemic Strokes that day receives diagnosis and treatment are research object, wherein man 36, female 17,43 years old~82 years old age
(61.7 ± 11.4 years old)；Using each research object peripheral blood T h2 cell percentages of flow cytomery；ELISA method detection
Th2 cell factors IL-4 concentration；The neural work(after ischemic cerebral stroke patients are admitted to hospital in 24 hours is assessed using NIHSS scorings
Can damage；Barthel indexes are used to assess ischemic cerebral stroke patients daily life self-care ability；Calculated using MRI or CT
Each research object infarction of brain area；Using each research object Th2 cell percentages of spass software analysis and its cell factor
The horizontal correlation with NIHSS scorings, Barthel indexes and infarction of brain area.
As a result show：(scoring score value is got over NIHSS scorings by peripheral blood Th2 cell percentages and its cell factor IL-4
Height, illustrate that nervous function damage is more serious) it is negatively correlated, be in Barthel indexes (score value is higher, and self care ability is higher)
Positive correlation, it is negatively correlated with cerebral apoplexy patient infarction of brain area (infarct size is bigger, and the state of an illness is more serious, and prognosis is poorer).
Result above shows that Th2 cell percentages and its cell factor IL-4 have with cerebral apoplexy especially cerebral arterial thrombosis
There is obvious correlation, Th2 cell percentages and its cell factor IL-4 can be diagnosed as cerebral apoplexy and the life of prognosis instruction
Thing mark, it is a kind of brand-new cerebral apoplexy mark, the two is with a wide range of applications.
Based on this, on the one hand, the invention provides Th2 cells as mark in cerebral apoplexy diagnostic kit is prepared
Using.
Further, in some embodiments of the present invention, the Th2 cells are the Th2 cells in peripheral blood.
Further, in some embodiments of the present invention, the cerebral apoplexy is cerebral arterial thrombosis.
On the other hand, the reagent of prediction patients with cerebral apoplexy prognosis is being prepared as mark the invention provides Th2 cells
Application in box.
Further, in some embodiments of the present invention, the Th2 cells are the Th2 cells of peripheral blood.
Further, in some embodiments of the present invention, the cerebral apoplexy is cerebral arterial thrombosis.
Another further aspect, cerebral apoplexy diagnostic kit or pre- is being prepared as mark the invention provides cell factor IL-4
The application surveyed in the kit of patients with cerebral apoplexy prognosis.
Further, in some embodiments of the present invention, the cerebral apoplexy is cerebral arterial thrombosis.
Further, in some embodiments of the present invention, the cell factor IL-4 is the cell in patients serum
Factor IL-4.
Also on the one hand, the invention provides cell factor IL-4 antibody to prepare cerebral apoplexy diagnostic kit or prediction brain
Application in the kit of apoplexy patient prognosis.
Further, in some embodiments of the present invention, above-mentioned cerebral apoplexy diagnostic kit or prediction cerebral apoplexy are suffered from
The kit of person's prognosis is ELISA kit, and it contains the cell factor IL-4 antibody for detecting cell factor IL-4.
Also on the one hand, the invention provides CD4+Antibody is preparing cerebral apoplexy diagnostic kit or prediction patients with cerebral apoplexy
Application in the kit of prognosis.
Further, in some embodiments of the present invention, above-mentioned cerebral apoplexy diagnostic kit or prediction cerebral apoplexy are suffered from
The kit of person's prognosis is ELISA kit, and it contains the CD4 for detecting Th2 cells+Antibody.
Be readily appreciated that, based on the present invention result of study on the basis of, it is any can specificity or non-specific binding
Cell factor IL-4 antibody, it may be incorporated for preparing cerebral apoplexy diagnostic kit or predict the reagent of patients with cerebral apoplexy prognosis
Box, cell factor IL-4 of the kit by enzyme-linked immunosorbent assay in individual sample level, according to thin
The intracellular cytokine IL-4 horizontal state of an illness to individual cerebral apoplexy is diagnosed or Index for diagnosis.
The feature and performance of the present invention are described in further detail with reference to embodiments.
Embodiment
1.1 research object
Choose central hospital of Xiangyang City of Hubei Province Neurology and receive diagnosis and treatment on April 6,6 days to 2017 March in 2017
53 Ischemic Strokes are research object, wherein man 36, female 17,43 years old to 82 years old (61.7 ± 11.4 age
Year).According to nineteen ninety-five national 4th cranial vascular disease meeting and 2007《Chinese cerebrovascular disease guideline of prevention and treatment》IS diagnosis
Standard, check and make a definite diagnosis through CT or MRI.The research obtains the approval of the moral ethics committee of central hospital of Xiangyang City, and according to country
Health research institute institutional review board regulations are implemented, and all patients for participating in the research sign informed consent form.
NIH stroke scale (the National Institutes of Health Stroke
Scale, NIHSS) it is used to assess the nervous function damage after Ischemic Stroke is admitted to hospital in 24 hours.NIHSS scores
Including 15 to degree：Degree of consciousness, ability of answering a question, the ability for deferring to instruction, eye movement, the visual field, facial muscular strength, upper limbs
Motor function, lower extremity motor function, limbs coordination, sensory function, language, structure sound, sensory neglect.Each scored to degree is 3
To 5 grades, scoring scope is 0~42 point, and fraction is higher to represent that nerve damage is more serious.All patients score according to NIHSS
It is divided into 3 groups：First group, NIHSS≤5 (man 14, female 3,60.2 ± 13.1 years old age)；Second group, 5 ＜ NIHSS ＜ 15
(man 15, female 10,61.8 ± 11.5 years old age)；3rd group, 15≤NIHSS (man 7, female 4,63.9 ± 8.4 years old)
Barthel indexes：It is used to assess ischemic cerebral stroke patients daily life self-care ability, detection project includes big
Urine, feed, modification, transfer, activity, wear the clothes, above downstairs etc..Score value is：It is slight to rely on, can complete independently more than 60 points
Part daily routines, but need part to help；Moderate relies on, and 60~41 points, it is necessary to which more help could complete daily life work
It is dynamic；Severe relies on ,≤40 points, and most ADLs all can not complete or need other people to look after.
Exclusion standard：Strictly exclude injury-ness brain hemorrhage, aneurysm or artery sclerosis, subarachnoid hemorrhage, itself
Any type of high fever (36.8 DEG C of T ＞), acute and chronic infectious in immunity disease, diabetes, operation, wound or blood sampling 2 weeks
History of disease；The cardiovascular and cerebrovascular diseases such as coronary heart disease, congenital heart disease, hypertensive cardiopathy, arrhythmia cordis；Thyroid function is low
Lower or hyperfunction, disease in the blood system, dysautonomia disease etc..
During research, some patients receive aspirin Antiplatelet therapy, another part patient receive Ticlopidine or
Person's clopidogrel Antiplatelet therapy is treated, and the slight patient of the small part state of an illness does not receive any treatment.Three groups of patients' is basic
Situation such as table 1.
The basic condition of 1 three groups of patients of table
1.2 material
Lymphocyte separation medium (lymphocyte separation medium) are produced by Mpbio companies；RPMI-1640
Culture medium is bought in Antgene companies；Cell stimulation cocktai (cell stimulatory agents) are bought in eBioscience
Company；HuCD4PE-Cy5RPA-T4, Hu IL-4PE 8D4-8 and Cytofix/Cytoperm (cell fix/penetrating kit)
Buy in BD PMG companies；Human IL-4 ELISA kits are bought in NeoBioscience companies；Phosphate
Buffered Saline (PBS-20X) are produced by CST companies；Centrifuge tube, EP pipes, streaming pipe are produced by Falcon companies；Pipette tips
Produced by GPL companies；Flow cytometer originates from Beckman Coulter companies.
1.3 PBMC collection
Each patient gathers 3ml peripheral bloods (Peripheral Blood after reception is admitted to hospital under early morning fasted conditions；
PB) into anticoagulant heparin pipe, gently shake up, blood specimen collection should be after symptom appearance in 24 hours.Add at ambient temperature etc.
The PBS dilutions of volume, gently shake up.15ml centrifuge tubes are taken, draw isometric Ficoll (lymphocyte separation medium) in centrifugation
Guan Zhong, pipe tilt 45 °, the PB after dilution are added slowly to above Ficoll liquid in Ficoll ullages about at 1cm along tube wall.
The blood handled well is put into 4 DEG C, in 2000r/min centrifuges, points four layers is centrifuged after 30min from ttom of pipe to liquid level, is successively
Red blood cell layer, layering liquid layer, PMBC layer (Peripheral Blood Mononuclear Cell, PBMC), blood
Pulp layer.2ml blood plasma is first drawn into EP pipes, -80 DEG C of refrigerators are put into, in case follow-up elisa assay.Pipette is inserted directly into cloud
Mist layer (PBMC layers), gentle aspiration cloud and mist layer, is put into new centrifuge tube.
1.4 statistical analysis
Measurement data is represented with mean ± standard deviation (X ± S)；Cytokine concentrations and the difference of cell percentages between group
Examined and assessed using t.P ＜ 0.05 illustrate that difference is statistically significant；Significantly significant difference variance between group
Analysis and evaluation.
1.5 Th2 cell percentages and the correlation with NIHSS scorings, Barthel indexes and infarct size
1.5.1 cell dyeing and FCM analysis Th2 cell percentages
The PBS of at least 3 times of PBMC volumes is added in centrifuge tube, 4 DEG C, 2000r/min centrifugation 5min, supernatant is abandoned, adds
1mlRPMI-1640 culture mediums (contain 10% hyclone), and piping and druming mixes.2ul cell stimulatory agents are added in culture medium, will
The culture medium is put into 37 DEG C, 5%CO2Cultivated in incubator.After stimulating culture 4h, 4 DEG C, 2000r/min centrifugation 5min, abandon
Clearly, then CD4 per 100ul systems 10ul is added+Antibody, 4 DEG C of lucifuges dye half an hour, flicked once within every 10 minutes.To be fully anti-
System after answering is washed with PBS, abandons supernatant, Cytofix Buffer are fixed.After half an hour, 2mlPBS, 4 DEG C, 2000r/ are added
Min centrifuges 5min, cleans 2 times, abandons supernatant, Permeabilization Buffer punchings.After half an hour, 2ml PBS are added, 4
DEG C, 2000r/min centrifugation 5min, abandon supernatant.Again plus the IL-4 antibody stainings per 100ul systems 10ul, 4 DEG C of lucifuge dyeing half are small
When, flick once within every 10 minutes.250ul PBS is added to be resuspended after PBS.It is put into detection Th2 cell percentages in flow cytometer
Than.
As a result as shown in Figure 1 (in figure：A is the representational fluidic cell figure of each group patient, and the percentage of positive cell is each
There is display in group figure；B is the comparative result of the Th2 cells expression of three groups of patients, wherein, * * * p<0.0001,*p<0.01),
By first group to the 3rd group, overall observation finds that Th2 cell percentages gradually decrease.
1.5.2 the detection of infarct size
All objects of observation receive CT after being admitted to hospital in 24h to 48h or MRI image checks, in order to ensure accurate
Property, nuclear magnetic resonance diffusion-weighted imaging is chosen to measure infarct size.When Diffusion-weighted imaging can not be obtained, use
Enhanced CT substitutes.Infarct area of edema is artificially drawn on every CT or MRI, and cm is all used in these regions2Represent.Such as
There is bleeding change in carpopodium dead zone, then hemorrhagic areas is just covered in infarct band.
1.5.3 the correlation analysis of Th2 cell percentages and NIHSS scorings, Barthel indexes and infarct size
NIHSS scorings are carried out to each patient, assess nervous function damage (the higher neural work(of explanation of scoring score value of patient
Can damage more serious), and correlation of the Th2 cell percentages with it is analyzed, as a result as shown in Figure 2 (in figure：A is Th2 percentages
With the correlation of NIHSS scorings；B is the correlation of Th2 percentages and Barthel indexes, and C is Th2 cell percentages and infarct
The correlation analysis of area).
Fig. 2 result is shown：NIHSS scoring reduces with the increase of Th2 percentages, illustrate Th2 cell percentages and
NIHSS scorings negatively correlated (Fig. 2-A, r=-0.599, p<0.0001)；
Barthel indexes (score value is higher, and self care ability is higher) increase, explanation with the increase of Th2 percentages
Th2 cell percentages and Barthel indexes are proportionate (Fig. 2-B, r=0.646, p<0.0001)；
Ischemic Stroke infarction of brain area reflects the order of severity and the prognosis of the state of an illness to a certain extent,
Cerebral apoplexy patient infarction of brain area is measured using CT or MRI, Fig. 2 is shown, infarct size is with Th2 cell percentages
The increase of ratio and reduce, illustrate Th2 cell percentages and the negatively correlated property of infarct size (Fig. 2-C, r=-0.593, p<
0.0001), i.e. Th2 cell percentages are higher, and patient's infarct size is lower.
Embodiment 2
The horizontal correlations with NIHSS scorings, Barthel indexes and infarct size of IL-4
2.1 ELISA method detection Th2 cell factors
Enzyme linked immunosorbent assay (ELISA) (Enzyme Linked Immunosorbent Assay, ELISA) is used to detect blood
Th2 cell factors IL-4 level in clear.Using IL-4ELISA kits, a standard items are diluted according to specification, in standard
50ul standard items are added in hole, treat to add 40ul sample diluting liquids and 10ul test serums in gaging hole.37 DEG C of temperature after shrouding film shrouding
Educate, liquid is abandoned after 30min, dry, fill it up with cleaning solution per hole, discard, be repeated 5 times after 30s, pat dry.In addition to blank well, add per hole
Enzyme marking reagent 50ul, it is upper for another example to incubate, wash.Per Kong Xianjia developer A50ul, then add developer B50ul, gently concussion is mixed
It is even, 37 DEG C of lucifuge colour developings.Add terminate liquid per hole after 15min.After blank zeroing, each hole extinction is measured successively under 450nm wavelength
Degree, and calculate cell factor IL-4 concentration.
The calculating of 2.2 NIHSS scorings, Barthel indexes and infarct size is the same as embodiment 1
The horizontal correlation analysis with NIHSS scorings, Barthel indexes and infarct size of 2.3 IL-4, is as a result shown in Fig. 3
(in figure：A is the horizontal correlations with NIHSS scorings of IL-4；B is IL-4 levels and the correlation of Barthel indexes, C IL-4
The horizontal correlation analysis with infarct size).
Fig. 3 result is shown：NIHSS scorings reduce with increase horizontal IL-4, illustrate that IL-4 is horizontal and are commented with NIHSS
Divide negatively correlated (Fig. 3-A, r=-0.622, p<0.0001)；
Barthel indexes increase with increase horizontal IL-4, illustrate that IL-4 is horizontal and are proportionate with Barthel indexes
(Fig. 3-B, r=0.611, p<0.0001)；
Infarct size reduces with increase horizontal IL-4, illustrates that IL-4 is horizontal and (schemes with the negatively correlated property of infarct size
3-C, r=-0.599, p<0.0001).
To sum up, present system have detected Th2 cell percentages in each research object PMBC, due to
NIHSS scorings are to reflect the common counter of the nervous function damage degree after patient admission in 24 hours, and Barthel indexes are
Reflect the common counter of patient's daily life self-care ability, the present invention have evaluated each research object NIHSS scorings and Barthel again
Index, and analyze correlation of the Th2 cells with the two.IL-4 is the main cell factor of Th2 cells, therefore be have detected each
IL-4 level in research object peripheral blood serum, and analyze IL-4 levels and NIHSS scorings and the phase of Barthel indexes
Guan Xing, protective effect of the Th2 cells to cerebral apoplexy is further verified from cytokine levels.Cerebral apoplexy patient infarction of brain area
Coincident with severity degree of condition can be directly reacted, therefore this research and utilization MRI or CT calculate each research object infarction of brain area, divide respectively
The horizontal property associated therewith of Th2 cells, IL-4 is analysed.As a result show, Th2 cell percentages and its cell factor IL-4 with
NIHSS scorings (scoring score value higher, illustrate that nervous function damage is more serious) are in inverse ratio, with Barthel indexes (score value is higher,
Self care ability is higher) it is proportionate, (infarct size is bigger, and the state of an illness is more serious, in advance with cerebral apoplexy patient infarction of brain area
It is poorer afterwards) it is in inverse ratio.
This indicates that Th2 cell percentages and its cell factor IL-4 have with cerebral apoplexy especially cerebral arterial thrombosis
Obvious correlation, Th2 cell percentages and its cell factor IL-4 can be diagnosed as cerebral apoplexy and the biology of prognosis instruction
Mark, it is a kind of brand-new cerebral apoplexy mark；Based on this, Th2 cells or cell factor IL-4 can be answered as mark
For preparing cerebral apoplexy diagnostic kit or preparing the medium field of kit of prediction patients with cerebral apoplexy prognosis, and cell
Factor IL-4 antibody and CD4+Antibody can also be used for cerebral apoplexy diagnostic kit or predict kit of patients with cerebral apoplexy prognosis etc.
Field, this provides a kind of new thinking and means for cerebral apoplexy diagnosis and prognosis, is advantageous to accelerate the pathogenesis of cerebral apoplexy
Flow of research, also provide help quickly to filter out the medicine for the treatment of cerebral apoplexy.
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (10)
- Application of the 1.Th2 cells as mark in cerebral apoplexy diagnostic kit is prepared.
- 2. application according to claim 1, it is characterised in that the Th2 cells are the Th2 cells in peripheral blood.
- 3. application according to claim 2, it is characterised in that the cerebral apoplexy is cerebral arterial thrombosis.
- Application of the 4.Th2 cells as mark in the kit for preparing prediction patients with cerebral apoplexy prognosis.
- 5. application according to claim 4, it is characterised in that the Th2 cells are the Th2 cells of peripheral blood.
- 6. application according to claim 5, it is characterised in that the cerebral apoplexy is cerebral arterial thrombosis.
- 7. cell factor IL-4 is preparing cerebral apoplexy diagnostic kit or is predicting the reagent of patients with cerebral apoplexy prognosis as mark Application in box.
- 8. application according to claim 7, it is characterised in that the cerebral apoplexy is cerebral arterial thrombosis.
- 9. application according to claim 7, it is characterised in that the cell factor IL-4 be patients serum in cell because Sub- IL-4.
- 10. cell factor IL-4 antibody is in preparing cerebral apoplexy diagnostic kit or predicting the kit of patients with cerebral apoplexy prognosis Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710544434.1A CN107345235A (en) | 2017-07-05 | 2017-07-05 | The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710544434.1A CN107345235A (en) | 2017-07-05 | 2017-07-05 | The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107345235A true CN107345235A (en) | 2017-11-14 |
Family
ID=60256964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710544434.1A Pending CN107345235A (en) | 2017-07-05 | 2017-07-05 | The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107345235A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109061139A (en) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | Application of the serum inflammatory biomarker in prevention and treatment acute cerebral ischemic infarction |
-
2017
- 2017-07-05 CN CN201710544434.1A patent/CN107345235A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| S. MAROUSI ET AL.: "Functional polymorphisms of interleukin 4 and interleukin 10 may predict evolution and functional outcome of an ischaemic stroke", 《EUROPEAN JOURNAL OF NEUROLOGY》 * |
| Y.-Q. TONG ET AL.3: "Association of variable number of tandem repeat polymorphism in the IL-4 gene with ischemic stroke in the Chinese Uyghur population", 《GENETICS AND MOLECULAR RESEARCH》 * |
| 孙颖等: "老年缺血性卒中合并急性肺损伤患者血清Th1/Th2细胞因子表达分析", 《细胞与分子免疫学杂志》 * |
| 黄廷富等: "人尿激肽原酶治疗非心源性缺血性脑卒中的疗效及其对免疫功能的影响", 《现代免疫学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109061139A (en) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | Application of the serum inflammatory biomarker in prevention and treatment acute cerebral ischemic infarction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Plata et al. | The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. | |
| Oshita et al. | Semi-quantitative procalcitonin test for the diagnosis of bacterial infection: clinical use and experience in Japan | |
| WO2021185124A1 (en) | Use of vitamin d binding protein as marker in diagnosis of mental illness depression | |
| González et al. | Utility of lateral flow tests in SARS-CoV-2 infection monitorization | |
| Marchetti et al. | Antiphospholipid antibodies and the risk of severe and non‐severe pre‐eclampsia: the NOHA case‐control study | |
| Scarano et al. | Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis | |
| Lu et al. | A survey on the status of semen analysis in 118 laboratories in China | |
| WO2012016333A1 (en) | Biomarkers for malaria | |
| Radovic et al. | Serum lactate as reliable biomarker of acute kidney injury in low-risk cardiac surgery patients | |
| Walle et al. | The role of platelet parameters for the diagnosis of preeclampsia among pregnant women attending at the University of Gondar Comprehensive Specialized Hospital antenatal care unit, Gondar, Ethiopia | |
| Scharnhorst et al. | A multicenter evaluation of a point of care CRP Test | |
| CN107345235A (en) | The application of Th2 cells and cell factor IL 4 as cerebral apoplexy mark | |
| CN108717123A (en) | A kind of method of joint-detection sFlt-1/PLGF and HLA-G detections pre-eclampsia | |
| Winangun et al. | Relationship of albumin serum levels and Neutrophil-Lymphocyte Ratios (NLR) on activities of daily living elderly patients with delirium at Sanglah General Hospital, Bali, Indonesia | |
| CN114636826B (en) | Application of CD177+ neutrophils in preparation of detection product for neonatal necrotizing enterocolitis | |
| Xiao et al. | A scoring system for assessing the severity of acute diarrhea of adult patients | |
| Thakar et al. | CD4 lymphocyte enumeration and hemoglobin assessment aid for priority decisions: a multisite evaluation of the BD FACSPresto™ system | |
| RU2803276C1 (en) | Method of prediction of cognitive disorders in patients with brain concusion and minor brain injury | |
| Courtney et al. | Prospective diagnostic accuracy assessment of the HemosIL HS D-dimer to exclude pulmonary embolism in emergency department patients | |
| CN106257287B (en) | Growth and differentiation factor 15 assesses the new opplication of the starting cerebral apoplexy of hyperpietic | |
| Ojengbede et al. | Comparative evaluation of haemoglobin estimation amongst pregnant women in Ibadan: Hemocue–B Haemoglobin analyzer versus haemiglobincyanide (Standard) method as the gold standard | |
| Adeyemo | ORIGINAL: Platelet Indices and Erythrocyte Sedimentation Rate are useful Parameters in the Assessment of a Cohort of Nigerian Women with Preeclampsia: West Afr J Med. 2022 Dec 29; 39 (12): 1273-1279. | |
| Sweilam et al. | Study the role of serum cartilage oligomericmatrix protein (COMP) in the diagnosis of rheumatoid arthritis patients | |
| Van der Merwe | Chronic stress and semen parameters | |
| Lockitch et al. | Prediction of fetal lung maturity by use of the Lumadex-FSI test. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171114 |